Mwn110

Phase 1

SShanghai Minwei Biotechnology Co., Ltd

Mwn110 is one of 4 therapeutic programs targeting Overweight , Obesity. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Overweight , ObesityNot yet recruiting

Overweight , ObesityPhase 1

Not yet recruiting

Competition

Competitive Landscape

6 competitors in Overweight , Obesity

#DrugCompanyPhaseTrials

Mwn109 1

SShanghai Minwei Biotechnology Co., Ltd

Phase 3

6 2

Mwn109 2

SShanghai Minwei Biotechnology Co., Ltd

Phase 3

6 3

Mwn109 3

SShanghai Minwei Biotechnology Co., Ltd

Phase 3

5 4

Mwn110

SShanghai Minwei Biotechnology Co., Ltd

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Not yet recruiting

Overweight , Obesity

NCT07779980

Clinical

Trials by Indication[1]

Overweight , Obesity1 trial

A Randomized, Double-Blind, Placebo-Controlled Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Subcutaneous Administrations of MWN110 Injection in Healthy Participants and Overweight or Obese Participants

Not yet recruiting·SShanghai Minwei Biotechnology Co., Ltd·Phase 1·NCT07779980·103 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Mwn110. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Mwn110. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Shanghai Minwei Biotechnology Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: SShanghai Minwei Biotechnology Co., Ltd

Mwn110

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Overweight , Obesity1 trial

References

Drug Info

Quick Facts

Related News